AbbVie Looks Expensive on GAAP Earnings, but Its Core Business Tells a Different Valuation Story

AbbVie can appear unusually expensive on a simple trailing price-to-earnings screen, but that headline multiple tells an incomplete story because reported earnings are being affected by acquisition-related and research-and-development charges.

The company’s operating performance remains strong. AbbVie reported second-quarter 2026 net revenue of $16.99 billion, up 10.2% year over year on a reported basis and 9.5% operationally. Adjusted diluted EPS rose 22.9% to $3.65.

The most important driver is the immunology portfolio. Skyrizi generated $5.505 billion of quarterly revenue, up 24.4% on a reported basis, while Rinvoq reached $2.525 billion, up 24.5%. Together, those products are more than offsetting the decline in Humira, which fell to $756 million as biosimilar competition continued to erode its legacy franchise.

That transition is strategically significant. For years, the central concern around AbbVie was whether the company could replace Humira. The current revenue mix provides strong evidence that Skyrizi and Rinvoq have become the new growth engine rather than simply temporary offsets.

The valuation confusion comes from the difference between GAAP and adjusted earnings. AbbVie reported GAAP EPS of $2.03 in the second quarter versus adjusted EPS of $3.65. The company’s 2026 adjusted EPS guidance is $13.87 to $14.07, and management noted that the range includes acquired IPR&D and transaction impacts already incurred or expected.

A trailing multiple based on depressed GAAP earnings can therefore make AbbVie look much more expensive than it appears on normalized earnings. Investors should not automatically ignore GAAP charges, because acquisitions require real capital and can destroy value if management overpays. But they should also avoid treating one-time deal accounting as if it permanently represents the earnings power of the existing business.

AbbVie’s growth is not limited to immunology. Its neuroscience portfolio generated $3.228 billion in Q2, up 20.3%, supported by Vraylar, Botox Therapeutic, Ubrelvy, Qulipta and Vyalev. That diversification reduces dependence on any one franchise, although immunology remains the largest contributor.

The company is also continuing to acquire pipeline assets. AbbVie announced an agreement to buy Apogee Therapeutics, which management expects to strengthen its immunology portfolio. The deal also introduces another layer of capital-allocation risk because investors must judge both the quality of the science and the price paid for future growth.

The bull case is straightforward: Skyrizi and Rinvoq continue compounding at double-digit rates, neuroscience grows, and pipeline investment extends the portfolio. The bear case is that valuation remains elevated while acquisitions consume capital and future growth fails to offset maturing products.

For investors, the cleanest way to analyze AbbVie is to reconcile reported earnings with adjusted earnings and then inspect the underlying cash generation. A high headline P/E is less informative when the denominator has been materially reduced by unusual transaction charges.

Cash flow provides another useful valuation check. AbbVie’s ability to generate substantial operating cash flow has historically supported dividends, debt reduction and business development. That matters because adjusted EPS is most credible when it is accompanied by durable cash generation. If acquisition spending rises faster than cash flow or leverage begins to climb materially, the adjusted multiple becomes less reassuring. Investors should therefore evaluate the stock on a three-part framework: core product growth, cash conversion and the return earned on newly deployed acquisition capital.

Dividend investors should also separate yield from valuation. AbbVie’s dividend is supported by cash generation, but a healthy payout does not make any entry price attractive. The strongest long-term setup would be continued Skyrizi and Rinvoq growth, stable cash conversion and disciplined acquisitions at a valuation that does not require perpetual double-digit growth. That combination would support both income and total-return potential.

BTI’s bottom line: AbbVie is not obviously cheap, but calling it dramatically overpriced based on GAAP trailing earnings alone is too simplistic. The core business is growing, the Humira replacement strategy is working, and normalized earnings provide a more useful starting point for valuation — with acquisition discipline remaining the key risk.